Adenosine Triphosphate (ATP) News and Research

RSS

Extensive, reversible changes in heart take place when exposed to low oxygen levels

From the highest mountaintop comes a new research report in the FASEB Journal that gets to the bottom of what happens to the hearts of people when exposed to low-levels of oxygen, such as those on Mount Everest or in the intensive care unit of a hospital.

1 Feb 2011

Prototype drug halts GVHD in mouse models of bone marrow transplantation

A prototype drug already shown to hold promise for treating autoimmune disorders like lupus, arthritis and psoriasis halts established graft-versus-host disease (GVHD) in mouse models of bone marrow transplantation, research at the University of Michigan and the University of Florida shows.

28 Jan 2011

75% of cell plasma membrane reversibly endocytosed

In three papers in the January and February issues of the Journal of General Physiology, Don Hilgemann and colleagues have extensively characterized a previously unidentified process by which up to 75% of the cell plasma membrane can be reversibly endocytosed.

18 Jan 2011

Critical tuning dial for controlling whole body energy

Researchers have found what appears to be a critical tuning dial for controlling whole body energy, according to a new report in the January issue of Cell Metabolism, a Cell Press publication. When energy levels within cells drop, it sets off a series of events designed to increase the amount of calorie-rich dietary fat that the body will absorb.

5 Jan 2011

Crothall partners with 3M to implement effective infection control

Crothall Healthcare, a premier provider of support services to healthcare clients, announced its Preferred Partnership arrangement with 3M to kick-off its powerfully enhanced approach to infection control.

29 Dec 2010

CMS increases reimbursement rate for Cylex's immune cell function assay by 267%

Cylex Incorporated® today announced that the Centers for Medicare and Medicaid Services (CMS) nearly tripled the reimbursement for ImmuKnow®, the immune cell function assay FDA-cleared for the detection of cell-mediated immune response in populations undergoing immunosuppressive therapy for organ transplant. This significant increase was granted in a time when the overall CMS clinical fee schedule experienced a comprehensive decrease in laboratory reimbursement rates.

15 Dec 2010

ArQule initiates enrollment in ARQ 736 Phase 1 clinical trial for advanced solid tumors

ArQule, Inc. today announced the commencement of patient dosing in a Phase 1 clinical trial with ARQ 736, a small molecule inhibitor of the RAF kinases.

7 Dec 2010

Mitochondrial dysfunction observed in children with full syndrome autism

Preliminary research has found that children with autism are more likely to have impaired mitochondrial function (structures within cells responsible for energy production) and mitochondrial DNA abnormalities than typically developing children, according to a study in the December 1 issue of JAMA.

1 Dec 2010

Scientists identify signaling pathway and receptor for thymosin beta 4

RegeneRx Biopharmaceuticals, Inc. nnounced that scientists have identified a long sought-after extracellular signaling pathway and receptor for thymosin beta 4 (Tβ4). The observation that Tβ4 increases cell surface ATP (energy produced by cells), could explain its ability to protect and regenerate tissue after ischemic injury and hypoxia (oxygen deficiency).

30 Nov 2010

Stealth Peptides introduces Bendavia clinical candidate at AHA Scientific Sessions

Stealth Peptides, a privately held biopharmaceutical company developing innovative mitochondrial therapies for diseases with significant unmet medical needs, introduced its lead clinical candidate, Bendavia, a novel compound that targets the mitochondrion, at the 2010 American Heart Association's (AHA) Scientific Sessions, Resuscitation Science Symposium.

22 Nov 2010

UH physicists study workings of PGK enzyme that may cause Alzheimer's, cancer

University of Houston physicists are using complex computer simulations to illuminate the workings of a crucial protein that, when malfunctioning, may cause Alzheimer's and cancer.

20 Nov 2010

Researchers identify small-molecule inhibitors that effectively target FAK enzyme in colon cancer

Researchers have identified two small-molecule inhibitors that effectively targeted the focal adhesion kinase (FAK), an enzyme present in certain cancers that helps tumors thrive and survive.

29 Oct 2010

Researchers create new high-content assay to increase human embryonic stem cell survival

A new technique for increasing the survival rates of human embryonic stem cells will revolutionize their use in drug discovery and therapy. Human embryonic stem cells often die during the process of isolation using enzymatic disaggregation or low-density plating, which limits their usefulness in drug discovery and basic research. Similarly, the low rate of attachment of implanted cells hinders cell therapy.

25 Oct 2010

Essentialis receives patent for active component in DCCR product

Essentialis, Inc. announced today that the United States Patent & Trademark Office (USPTO) has issued U.S. Patent No. 7,799,777 entitled Salts of potassium ATP channel openers and uses thereof. The patent claims a novel composition of a polymorph of diazoxide choline, the active ingredient in the Essentialis lead product, DCCR. Essentialis has successfully completed phase 2b clinical trials with DCCR, showing a highly significant triglyceride reduction in dyslipidemic patients.

12 Oct 2010

Neuro-Biotech introduces biomarker for progressive clinical investigation on Alzheimer's Disease

Neuro-Biotech Corporation introduces a Neuro-biomarker which is linked to a series of Neuro-Bio tests. This will permit to understand the science behind them and how they each will contribute to a progressive clinical investigation involving the input and output of the brain.

5 Oct 2010

Researchers discover HIV-1 resists AZT drug

Rutgers researchers have discovered how HIV-1, the virus that causes AIDS, resists AZT, a drug widely used to treat AIDS. The scientists, who report their findings in Nature Structural & Molecular Biology, believe their discovery helps researchers understand how important anti-AIDS treatments can fail and could help AIDS researchers develop more effective treatment for the disease.

20 Sep 2010

Mechanism linking brain activity to sleep discovered

Washington State University researchers have discovered the mechanism by which the brain switches from a wakeful to a sleeping state. The finding clears the way for a suite of discoveries, from sleeping aids to treatments for stroke and other brain injuries.

15 Sep 2010

New gene required for memory formation identified

A team led by a Scripps Research Institute scientist has for the first time identified a new gene that is required for memory formation in Drosophila, the common fruit fly. The gene may have similar functions in humans, shedding light on neurological disorders such as Alzheimer's disease or human learning disabilities.

9 Sep 2010

Afferent Pharmaceuticals' P2X3 receptor antagonist reduces bladder hyperactivity

Afferent Pharmaceuticals, a clinical-stage biopharmaceutical company developing first-in-class, small molecule compounds that target P2X3 receptors, today announced preclinical in vivo results demonstrating that an investigational P2X3 receptor antagonist reduced experimentally induced bladder hyperactivity.

26 Aug 2010

Discovery of Hsp90 protein's pattern of motion paves way for new drug target in cancer therapy

The protein Hsp90 plays a significant role in the survival of cells that are exposed to stress. Researchers at the Technische Universitaet Muenchen (TUM) uncovered this protein's mode of operation some time ago - but now Hsp90 has surprised even the experts with an unexpected pattern of motion. The results are published in the current online issue of the renowned science journal PNAS and may help researchers discover specific cancer medication.

24 Aug 2010